Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kimball

Showing results (331-340 of 373) with videos related to

Pageof 38
Sort By:
The British Journal of Dermatology|April 5, 2024
Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trialAfsaneh Alavi, Errol P Prens, Alexa B Kimball, et al.
Dermatology and Therapy|August 8, 2023
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD StudyAlexa B Kimball, Dimittri Delevry, Min Yang, et al.
Journal of the American Academy of Dermatology|December 14, 2011
Increased diagnosis of thin superficial spreading melanomas: A 20-year studyJason E Frangos, Lyn M Duncan, Adriano Piris, et al.
Journal of the American Academy of Dermatology|September 30, 2014
OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year resultsAlexa B Kimball, Kenneth J Rothman, Gregory Kricorian, et al.
JAMA Dermatology|March 18, 2026
Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical TrialAlexa B Kimball, Konrad T Sawicki, Lindsay Ackerman, et al.
Journal of the American Academy of Dermatology|November 6, 2017
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)Bruce Strober, Melinda Gooderham, Elke M G J de Jong, et al.
The Journal of Dermatological Treatment|December 20, 2012
Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severityMona L Martin, Kelly P McCarrier, Chiun-Fang Chiou, et al.
Lancet (London, England)|June 10, 2017
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trialsKristian Reich, Kim A Papp, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology|February 9, 2016
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Bruce E Strober, Robert Bissonnette, David Fiorentino, et al.
Drug Safety|July 15, 2024
Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing ReportsUma Mahadevan, Gweneth Levy, Lianne Gensler, et al.
Pageof 38

Showing results (331-340 of 373) with videos related to

Sort By:
Pageof 38
The British Journal of Dermatology|April 5, 2024
Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trialAfsaneh Alavi, Errol P Prens, Alexa B Kimball, et al.
Dermatology and Therapy|August 8, 2023
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD StudyAlexa B Kimball, Dimittri Delevry, Min Yang, et al.
Journal of the American Academy of Dermatology|December 14, 2011
Increased diagnosis of thin superficial spreading melanomas: A 20-year studyJason E Frangos, Lyn M Duncan, Adriano Piris, et al.
Journal of the American Academy of Dermatology|September 30, 2014
OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year resultsAlexa B Kimball, Kenneth J Rothman, Gregory Kricorian, et al.
JAMA Dermatology|March 18, 2026
Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical TrialAlexa B Kimball, Konrad T Sawicki, Lindsay Ackerman, et al.
Journal of the American Academy of Dermatology|November 6, 2017
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)Bruce Strober, Melinda Gooderham, Elke M G J de Jong, et al.
The Journal of Dermatological Treatment|December 20, 2012
Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severityMona L Martin, Kelly P McCarrier, Chiun-Fang Chiou, et al.
Lancet (London, England)|June 10, 2017
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trialsKristian Reich, Kim A Papp, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology|February 9, 2016
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Bruce E Strober, Robert Bissonnette, David Fiorentino, et al.
Drug Safety|July 15, 2024
Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing ReportsUma Mahadevan, Gweneth Levy, Lianne Gensler, et al.
Pageof 38